1-6 of 6
Christos S. Karapetis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials

Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, Dongsheng Tu, Stephanie Y. Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O'Callaghan, Jonathan M. Loree
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1121–1130.
https://doi.org/10.1158/1078-0432.CCR-23-3275
Published: 15 March 2024
View article titled, Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Open the PDF for Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

Jonathan M. Loree, Anthony Dowers, Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O'Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 52–59.
https://doi.org/10.1158/1078-0432.CCR-20-2710
Published: 04 January 2021
View article titled, Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Open the PDF for Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial in another window
Includes: Supplementary data
Journal Articles

Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5487–5493.
https://doi.org/10.1158/1078-0432.CCR-20-1876
Published: 15 October 2020
View article titled, Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Open the PDF for Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab in another window
Includes: Supplementary data
Journal Articles

Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab

Ashley M. Hopkins, Ganessan Kichenadasse, Elizabeth Garrett-Mayer, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3280–3286.
https://doi.org/10.1158/1078-0432.CCR-19-2968
Published: 01 July 2020
View article titled, Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
Open the PDF for Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab in another window
Includes: Supplementary data
Journal Articles

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer

Geoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie A. Sullivan, Zhuo Chen, Eric Morgen, John Simes, Timothy J. Price, Niall C. Tebbutt, Jeremy D. Shapiro, G. Mark Jeffery, J. Daniel Mellor, Thomas Mikeska, Shakeel Virk, Lois E. Shepherd, Derek J. Jonker, Christopher J. O'Callaghan, John R. Zalcberg, Christos S. Karapetis, Alexander Dobrovic
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2435–2444.
https://doi.org/10.1158/1078-0432.CCR-15-0414
Published: 12 May 2016
View article titled, Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Open the PDF for Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

Christos S. Karapetis, Derek Jonker, Manijeh Daneshmand, Jennifer E. Hanson, Christopher J. O'Callaghan, Celia Marginean, John R. Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy J. Price, Jeremy D. Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, Ursula Lee, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer, for the NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (3): 744–753.
https://doi.org/10.1158/1078-0432.CCR-13-0606
Published: 02 February 2014
View article titled, <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
Open the PDF for <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 in another window